AMEX · MSOS
Financial Services · Asset Management
$4.08
Down-$0.02 (-0.49%)
Updated Oct 15, 2026, 4:41 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MSOS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
MSOS closed at $4.08 after 21 trading sessions, down 17.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $4.16 | $4.24 | $4.0101 | $4.08 | 6.89M |
| Oct 13, 2026 | $4.21 | $4.2487 | $4.095 | $4.10 | 4M |
| Oct 12, 2026 | $4.31 | $4.34 | $4.185 | $4.20 | 2.81M |
| Oct 9, 2026 | $4.31 | $4.35 | $4.21 | $4.34 | 2.81M |
| Oct 8, 2026 | $4.46 | $4.47 | $4.19 | $4.27 | 6.8M |
| Oct 7, 2026 | $4.44 | $4.505 | $4.405 | $4.47 | 2.74M |
| Oct 6, 2026 | $4.41 | $4.53 | $4.39 | $4.45 | 2.75M |
| Oct 5, 2026 | $4.47 | $4.50 | $4.35 | $4.39 | 4.51M |
| Oct 2, 2026 | $4.65 | $4.68 | $4.35 | $4.47 | 8.75M |
| Oct 1, 2026 | $4.54 | $4.655 | $4.44 | $4.60 | 3.1M |
| Sep 30, 2026 | $4.753 | $4.765 | $4.40 | $4.52 | 20.3M |
| Sep 29, 2026 | $5.17 | $5.185 | $5.06 | $5.09 | 5.25M |
| Sep 28, 2026 | $5.12 | $5.225 | $5.02 | $5.16 | 3.19M |
| Sep 25, 2026 | $5.17 | $5.22 | $5.06 | $5.16 | 3.81M |
| Sep 24, 2026 | $5.34 | $5.3653 | $5.125 | $5.18 | 8.73M |
| Sep 23, 2026 | $5.31 | $5.44 | $5.255 | $5.43 | 5.74M |
| Sep 22, 2026 | $4.99 | $5.34 | $4.94 | $5.33 | 10.16M |
| Sep 21, 2026 | $4.93 | $5.065 | $4.86 | $4.94 | 3.87M |
| Sep 18, 2026 | $4.96 | $4.9798 | $4.75 | $4.90 | 5.42M |
| Sep 17, 2026 | $4.90 | $5.0305 | $4.90 | $4.96 | 2.52M |
| Sep 16, 2026 | $4.945 | $4.99 | $4.84 | $4.92 | 2.12M |
The latest Smart Investors Daily articles mentioning MSOS.
Company
Market Activity
Research & News
MSOS research
Company profile and research snapshot.
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Curaleaf has raised its hostile bid for Aurora Cannabis to $5 per share as Schedule III tax relief fuels cannabis M&A, with Tilray's Oct. 8 earnings seen as a sector barometer.
SeekingAlpha · Oct 1, 2026
AdvisorShares Pure US Cannabis ETF is reiterated as a Buy despite DEA rescheduling delays. Click to see MSOS valuation, Trulieve Cannabis upside, and key risks.
Yahoo · Sep 30, 2026
The DEA just hit pause on cannabis rescheduling, putting the sector’s biggest catalyst and a potentially massive 280E tax break back in limbo.
Yahoo · Sep 30, 2026
Key TakeawaysTrulieve shares fell about 14% after a DEA administrative law judge paused the case on moving marijuana to Schedule III on Tuesday afternoon. The pause followed a September 23 GAO report on drug scheduling, which the parties opposing rescheduling used to ask for the stay.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MSOS.
